Breaking News

Apr 9, 20211 min read

KRAS Kickers featured at AACR

American Association for Cancer Research (AACR) is the first and largest cancer research organization dedicated to accelerating the...

Mar 25, 20213 min read

Adagrasib for Patients With Advanced KRAS G12C–Mutated NSCLC

Treatment with the KRAS G12C inhibitor adagrasib showed clinical activity in patients with advanced non–small cell lung cancer (NSCLC)...

Mar 24, 20213 min read

Second Drug Targeting KRAS G12C Shows Benefit in Mutated Non-Small-Cell Lung Cancer

Clinical activity with a second drug inhibiting KRASG12C confirms its role as a therapeutic target in patients with advanced...

Mar 11, 202114 min read

Lilly Announces Details of Presentations at 2021 American Association for Cancer Research

Eli Lilly and Company (NYSE: LLY) today announced that data from programs across its oncology portfolio and pipeline will be presented at...

Mar 11, 20212 min read

Lilly rejoins KRAS race with swipe at Amgen and Mirati, plans 2021 clinical trial

Eli Lilly has rejoined the KRAS race months after toxicity forced it to dump its first candidate. The Big Pharma is set to enter phase 1...

Mar 6, 20217 min read

The Epic Battle with Cancer's 'Death Star'

David Cox Forty years after the mutant genes that cause the deadliest cancers were discovered, drugs that target them could be approved...

Feb 5, 20214 min read

How Scientists Shot Down Cancer’s ‘Death Star’

Gina Kolata No drug could touch a quivering protein implicated in a variety of tumors. Then one chemist saw an opening. After 40 years of...

Jan 25, 20213 min read

Sotorasib Provides Durable Clinical Benefit for Patients with NSCLC and KRAS Mutations

IASLC Exciting New Research to be Presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer’s...

Jan 19, 202123 min read

The Improbable Targeted Therapy: KRAS as an Emerging Target in Non-Small Cell Lung Cancer

KRAS is a frequent oncogenic driver in solid tumors, including non-small cell lung cancer (NSCLC). It was previously thought to be an...

SPARK study: Studying Pathways of Resistance in KRAS-driven Cancers

Brief Summary “Up to 250 patients from anywhere in the United States can remotely consent and participate to have plasma drawn locally...

Revolution Medicines: RMC-6236 Pancreatic Cancer Update to Support Pivotal Phase 3 Trial

Rev Med reports out on the 46% of the pancreatic cancer patients who were enrolled in NCT05379985 (54% of patients are NSLC or other...

Hug from Brenda

'I'm a woman of faith. I know where I'm going' These words were a gift to me from Brenda giving me comfort. The love this beautiful ...